Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Several promising strategies based on combining or cycling different antibiotics have been
proposed to increase efficacy and counteract resistance evolution, but we still lack a deep …

Leishmaniasis is regarded as a neglected tropical disease by World Health Organization
(WHO) and is ranked next to malaria as the deadliest protozoan disease. The primary …

The remarkable ability of Mycobacterium tuberculosis to survive attacks from the host
immune response and drug treatment is due to the resilience of a few bacilli rather than a …

Tuberculosis (TB) is among the most difficult infections to treat, requiring several months of
multidrug therapy to produce a durable cure. The reasons necessitating long treatment times …

Caseous necrosis is a hallmark of tuberculosis (TB) pathology and creates a niche for drug-
tolerant persisters within the host. Cavitary TB and high bacterial burden in caseum require …

Mycobacterium tuberculosis (M. tb), a bacterial pathogen that causes tuberculosis disease
(TB), exerts an extensive burden on global health. The complex nature of M. tb, coupled with …

A challenge in tuberculosis treatment regimen design is the necessity to combine three or
more antibiotics. We narrow the prohibitively large search space by breaking down high …

Introduction Tuberculosis requires lengthy multi-drug therapy. Mycobacterium tuberculosis
occupies different tissue compartments during infection, making drug access and …

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), accounts for
over ten million infections and over 1.5 million deaths every year [1]. Upon infection, the …